In vitro evidences for glucosensing capacity and mechanisms in hypothalamus, hindbrain, and Brockmann bodies of rainbow trout.
We aimed to support in vitro the glucosensing capacity observed in vivo in rainbow trout hypothalamus, hindbrain, and Brockmann bodies (BB) and to obtain preliminary evidence of the mechanisms involved. The response of parameters involved in the glucosensing capacity [hexokinase, hexokinase IV (glucokinase), and pyruvate kinase activities and glucose and glycogen levels] was assessed in these tissues incubated for 1 h with 2, 4, or 8 mM D-glucose alone (control) or with specific agonists/inhibitors of the steps involved in glucosensing capacity in mammals. These agents were a competitor for glucose phosphorylation (15 mM mannose), sulfonylurea receptor-1 effectors (500 microM tolbutamide or diazoxide), glycolytic intermediates (15 mM glycerol, lactate, or pyruvate), and inhibitors of glucose transport (10 microM cytochalasin B), glycolysis [20 mM 2-deoxy-D-glucose (2-DG)], and L-type calcium channel (1 microM nifedipine). Control incubations of the three tissues displayed increased glucose and glycogen levels and glucokinase activities in response to increased medium glucose, thus supporting our previous in vivo studies. Furthermore, critical components of the glucosensing mammalian machinery are apparently functioning in the three tissues. The responses in brain regions to all substances tested (except 2-DG and nifedipine) were similar to those observed in mammals, suggesting a similar glucosensing machinery. In contrast, in BB, only the effects of 2-DG, lactate, pyruvate, diazoxide, and nifedipine were similar to those of mammalian beta-cells, suggesting that some of the components of the piscine glucosensing model are different than those of mammals. Such differences may relate to the importance of amino acids rather than glucose signaling in the trout BB.
Polakof
Sergio
S
Laboratorio de Fisioloxía Animal, Facultade de Bioloxía, Edificio de Ciencias Experimentais, Universidade de Vigo, E-36310 Vigo, Spain.
Míguez
Jesús M
JM
Soengas
José L
JL
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D003571:Cytochalasin B / Q000494:pharmacology; D003847:Deoxyglucose / Q000494:pharmacology; D003981:Diazoxide / Q000494:pharmacology; D005941:Glucokinase / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D006003:Glycogen / Q000378:metabolism; D006019:Glycolysis / Q000187:drug effects; D006593:Hexokinase / Q000378:metabolism; D007031:Hypothalamus / Q000201:enzymology / Q000378:metabolism*; D066298:In Vitro Techniques; D007700:Kinetics; D008358:Mannose / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D017686:Oncorhynchus mykiss / Q000502:physiology*; D010766:Phosphorylation; D015221:Potassium Channels / Q000378:metabolism; D011770:Pyruvate Kinase / Q000378:metabolism; D012249:Rhombencephalon / Q000201:enzymology / Q000378:metabolism*
D002121:Calcium Channel Blockers; D015221:Potassium Channels; D003571:Cytochalasin B; D006003:Glycogen; D003847:Deoxyglucose; D006593:Hexokinase; D005941:Glucokinase; D011770:Pyruvate Kinase; D009543:Nifedipine; D005947:Glucose; D003981:Diazoxide; D008358:Mannose